<DOC>
	<DOCNO>NCT00778115</DOCNO>
	<brief_summary>The objective study compare relative bioavailability Loperamide HCl 2 mg simethicone 125 mg tablet ( Ranbaxy ) ImodiumÂ® Advanced caplets ( McNeil ) healthy subject fast condition</brief_summary>
	<brief_title>Bioequivalence Study Loperamide Hydrochloride 2 mg Simethicone 125 mg Tablet Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct single-dose , randomize , 2-period sequence crossover study fast condition compare equal dose test reference product interval period least 7 day . The period confinement least 10 hour dose 24 hour blood collection period . Subjects ask return clinic subsequent blood circulation Twenty-six subject ( 26 ) recruit study twenty-three ( 23 ) complete clinical portion study . Subject # 17 withdrawn sponsor 's representative due adverse event unrelated drug ) , subject # 18 subject # 25 voluntarily withdraw due adverse event</detailed_description>
	<mesh_term>Loperamide</mesh_term>
	<mesh_term>Antidiarrheals</mesh_term>
	<mesh_term>Simethicone</mesh_term>
	<criteria>1 . All subject select sudy least 18 year age 2 . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history 3 . Each female subject give serum pregnancy test part prestudy screen process At end study , subject exit evaluation , clinical laboratory measurement Adequate blood urine sample obtain within 28 day begin first period end clinical laboratory measurement Clinical laboratory measurement include haematology , clinical chemistry , urine analysis , HIV screen , HepatitisB , C screen , Drugs abuse screen Subject candidate meet follow criterion exclude : : 1 . Subjects history alcoholism drug addiction ( past 2 year ) , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study 2 . Subjects whose clinical laboratory test outside normal range may retested request clinical investigator . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant 3 . Subjects history allergic response class drug test exclude study 4 . All subject urine sample assay presence drug abuse part clinical laboratory screen procedure checkin . Subjects found urine concentration test drug allow participate 5 . Subjects donate blood and/ plasma least 30 day prior first dose study 6 . Subjects take investigational drug within 30 day prior first dose study 7 . Female subject pregnant , breast feeding , likely become pregnant study allow participate . Female subject child bear potential must either abstain sexual intercourse use reliable barrier method ( eg . Condom , IUD ) contraception course study allow participate . Subjects use implant injected hormonal contraceptive 14 day dose allow participate 8 . All female subject screen pregnancy checkin period . Subjects positive inconclusive result withdraw study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence Loperamide HCl 2 mg simethicone 125 mg tablet</keyword>
</DOC>